

**Curriculum Vitae: Andreas CERNY, 4.3.1956, from Stein (SG)**

**Home address:** Via F. Somaini 9, 6900 Lugano, Tel./Fax: ++ 41 91 967 28 15

**Hospital address:** Epatocentro Ticino, Via Soldino 5, 6900 Lugano, Tel: ++41 91 960 85 03,  
Fax: ++ 41 91 960 87 18, e-mail: andreas.cerny@bluewin.ch, web www.epatologia.ch

Reparto di Medicina Interna, Clinica Luganese Moncucco, Lugano, Via Moncucco 10, 6900  
Lugano, Tel.: ++ 41 91 960 81 11, www.clinicaluganese.ch

### **Education**

- Medical School, University of Berne, Switzerland, 1975-1981, Federal diploma 1981.
- Postgraduate Course in Experimental Medicine and Biology, Faculty of Medicine, University of Zürich, 1982-1983.
- VQE (Visa qualifying examination, USA) and ECFMG, 1983.
- Course of Management and Economy in the Health Care Field (MEGS) of the University of Italian Switzerland (Università della Svizzera Italiana), 1999-2002
- European Center of Pharmaceutical Medicine in Basel: ECPM course 9/2001-6/2003. Diploma for Pharmaceutical Medicine, July 2003.

### **Training**

- 4/1982-3/1986: Research Fellow, Institute for Experimental Pathology, University of Zürich (R.M. Zinkernagel, MD, Nobel prize 1996).
- 4/1986-3/1987: Resident, Internal Medicine and Pneumology, Bernische Höhenklinik Heiligenschwendi (U. Wildbolz, MD).
- 7/1987-6/1988: Resident, Internal Medicine, Regionalspital Burgdorf (A. Gerber, MD).
- 5/1988-9/1988: Research Fellow, Laboratory of Immunopathology, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA, (H.C. Morse III, MD).
- 10/1988-2/1991: Senior Resident, Internal Medicine (F.A. Waldvogel, MD) and Division of Infectious Diseases (D. Lew, MD) University Hospital, Geneva. Research in the Laboratories for Viral Serology (L. Perrin, MD) and Immunopathology (S. Izui, MD).
- 3/1991-6/1992: Attending physician (Oberarzt) , Internal Medicine, Zieglerspital Bern (K.A. Neftel, MD).
- 7/1992-6/1993: Senior Research Fellow, Dept. of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA (F.V. Chisari, MD).

- 6/1993-4/1995: Attending physician (Oberarzt), Department of Medicine, Inselspital, University Hospital Berne (Prof. P.W. Straub, MD), Consultant in infectious diseases. Teaching in internal medicine and infectious diseases.
- 4/1995-2/1996: Visiting Fellow, Program in Infectious Diseases, Fred Hutchinson Cancer Center und University of Washington, Seattle, WA, USA (L. Corey MD, R. Bowden MD)
- 3/1996-6/1999: Attending physician (Oberarzt), Department of Medicine, Inselspital, University Hospital Berne (Prof. P.W. Straub, MD), Consultant in infectious diseases. Teaching in internal medicine and infectious diseases. Acting head Clinical Investigation Unit of the Division of General Internal Medicine. Deputy Chair (Chefarztstellvertreter) Dept. of General Internal Medicine since January 1st. 1997. Rotation at the Institute of Clinical Pharmacology, University of Berne (Proff. J. Reichen and B. Lauterburg)
- 7/1999-12/2006: Chief Department of Internal Medicine, Ospedale Civico, Lugano, Switzerland and 7/2002-12/06 Founding Director, Regional Farmacovigilance Center of Ticino in Lugano.

### **Academic and Specialty Titles**

- Doctorate: "Suppression of B-cell development and antibody production in mice with polyclonal rabbit and monoclonal rat anti-IgM antibodies: I. Characterization of the suppressed state." Medizinische Fakultät der Universität Zürich, Prof. R.M. Zinkernagel, (16.12.1985).
- FMH Speciality title in Internal Medicine (13.6.1991).
- FMH Speciality title in Infectious Diseases (23.12.1999).
- FMH Speciality title in Pharmaceutical Medicine (11.12.2004).
- Habilitation: "Untersuchungen zur Pathogenese von AIDS im Mausmodell" Medizinische Fakultät der Universität Bern (2.3.1995).
- Professor of Medicine (Honorarprofessor), University of Bern (25.6.2002).

### **Current appointments**

- 1/2007-present: Attending physician Internal Medicine, Clinica Luganese, sede Moncucco, Lugano, Switzerland.
- Head "Weiterbildungstätte" in Internal Medicine Category C for 1 year at the Clinica Luganese Moncucco.
- 7/2013-present: Director Epatocentro Ticino SA
- Chairman Fondazione Epatocentro Ticino and director of the Clinical Trial Unit (CTU)

- Private practice: with Dr's S. Mossi, H. Schaufelberger, C. Quattropani, S. Vanini (Gastroenterology FMH) Via Trevano 38, 6900 Lugano and Corso S. Gottardo 6, 6830 Chiasso.
- Member of the Human Medicines Expert Committee (HMEC) of Swissmedic since 6/2004 ([www.swissmedic.ch](http://www.swissmedic.ch))
- Member on the National Vaccine Pharmacovigilance Committee of Swissmedic,
- Member of the "Commissione Cantonale Sperimentazione sugli Animali" of the Canton Ticino
- Council Member, Swiss Experts in Viral Hepatitis (SEVHEP, [www.sevhep.ch](http://www.sevhep.ch)) (past president 12/2008-10/2013)
- Council Member of the Swiss Association for the Study of the Liver (SASL, [www.sasl.ch](http://www.sasl.ch))
- Council Member of the Swiss Hepatitis C Cohort Study ([www.swisshcv.ch](http://www.swisshcv.ch))
- Council Member of the Swiss Society of Internal Medicine ([www.sgim.ch](http://www.sgim.ch))
- Council Member of FORMVI (Fondazione per la Ricerca sulle malattie Virali)

#### **Principal Areas of Expertise and Interests**

Expertise includes basic and clinical research in the fields of immunology, virology and infectious diseases especially viral hepatitis. The experience spans both animal models of acute (VSV) and chronic viral infections (LCMV, MAIDS), autoimmunity as well as human antiviral immunology mostly in hepatitis C and B including preclinical vaccine development to HCV.

The clinical training and experience includes **internal medicine, infectious diseases, hepatology, transplantation medicine, drug and vaccine safety and pharmacovigilance**. The experience in pharmaceutical medicine includes conduction of a large number of drug trials mostly phases II and III in many diverse clinical indications as director of the Clinical Investigation Unit of the Inselspital since 1996 and from 1999 on in Ticino.

The academic teaching to medical students and physicians in training includes all fields of Internal Medicine with an emphasis on pharmacotherapy, drug safety, hepatology, infectious diseases applying the principles of evidence-based medicine (EBM). Academic experience includes direction of 5 doctoral theses for PhD's and 5 for MD's at the University of Bern.

A) Originals (peer-review since 2008)

65. Yerly D, Heckerman D, Allen TM, Chisholm JV 3rd, Faircloth K, Linde CH, Frahm N, Timm J, Pichler WJ, Cerny A, Brander C. Increased CTL epitope variant cross-recognition and functional avidity are associated with HCV clearance. *J Virol.* 2008 Jan 9;
66. Helbling B, Overbeck K, Gonvers JJ, Malinverni R, Dufour JF, Borovicka J, Heim M, Cerny A, Negro F, Bucher S, Rickenbach M, Renner EL, Mullhaupt B; Swiss Hepatitis C Cohort Study. Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. *Gut.* 2008 Nov;57(11):1597-603
67. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze zur Wiesch J, Ledlie T, Koehrsen M, Kodira K, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein MF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients. *Hepatology* 2008, 48:1769-1778.
68. Ciuffreda D, Comte D, Cavassini M, Giostra E, Bühler L, Perruchoud M, Heim MH, Battegay M, Genné D, Mulhaupt B, Malinverni R, Oneta C, Bernasconi E, Monnat M, Cerny A, Chuard C, Borovicka J, Mentha G, Pascual M, Gonvers JJ, Pantaleo G, Dutoit V. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. *Eur J Immunol.* 2008 Oct;38(10):2665-77
69. Prasad L, Spicher VM, Negro F, Rickenbach M, Zwahlen M; Swiss Hepatitis C Cohort Study Group. Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study. *J Viral Hepat.* 2009 Sep;16(9):644-9.
70. C. Bochud PY, Cai T, Overbeck K, Bochud M, Rickenbach M, Dufour JF, Muellhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P and Negro F, on behalf of the Swiss Hepatitis C Cohort Study Group\* Genotype 3 is Associated with Accelerated Fibrosis Progression in Chronic Hepatitis *J Hepatol* 2009 Oct;51(4):655-66
71. Sgier C, Müllhaupt B, Gerlach T, Moradpour D, Negro F, Malé PJ, Heim MH, Malinverni R, Cerny A, Dufour JF. Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C. *J Viral Hepat.* 2010 Jan 13. [Epub ahead of print]
72. Rauch A, Kutalik Z, Descombes P, Cai T, di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY; Swiss Hepatitis C and HIV Cohort Studies. Genetic variation in IL28B Is Associated with Chronic Hepatitis C and Treatment Failure - A Genome-Wide Association Study. *Gastroenterology.* 2010 Jan 7. [Epub ahead of print]
73. Overbeck K, Dufour JF, Müllhaupt B, Helbling B, Borovicka J, Malinverni R, Heim M, Moradpur D, Cerny A, Rickenbach M, Negro F. Impact of international consensus

guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland. *Swiss Med Wkly*. 2010 Feb 3.

74. Schwendener RA, Ludewig B, Cerny A, Engler O. Liposome-based vaccines. *Methods Mol Biol*. 2010;605:163-75.
75. Bihl F, Russmann S, Gurtner V, Di Giammarino L, Pizzi-Bosman L, Michel M, Cerny A, Hadengue A, Majno P, Giostra E, Castelli D, Mentha G. Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation. *BMC Gastroenterol*. 2010 Jul 4;10:71
76. Gonvers JJ, Heim MH, Cavassini M, Müllhaupt B, Genné D, Bernasconi E, Borovicka J, Cerny A, Chave JP, Chuard C, Dufour F, Dutoit V, Malinverni R, Monnat M, Negro F, Troilliet N, Oneta C. Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. *Swiss Med Wkly*. 2010 Jul 19;140:w13055
77. Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, Sarrazin C, Balciuniene L, Feinman SV, Faruqi R, Pedicone LD, Esteban R; SUCCESS Study Investigators. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. *Hepatology*. 2010 Oct;52(4):1201-7.
78. Adami M, Marsteller I, Mazzucchelli L, Cerny A, Bernasconi E, Bertoli R. Granulomatous hepatitis after intravesical bacillus Calmette-Guérin treatment. *Scand J Infect Dis*. 2011 Jan;43(1):55-7.
79. Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud PY; On Behalf Of The Swiss Hepatitis C Cohort Study Group. Viral Genotype-Specific Role of PNPLA3, PPARG, MTTP and IL28B in Hepatitis C Virus-Associated Steatosis. *J Hepatol*. 2011 Sep;55(3):529-35
80. Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, Dollenmaier G, Dufour JF, Gerlach TJ, Heim MH, Malinverni R, Müllhaupt B, Negro F, Moradpour D, Bochud PY; Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon- $\alpha$  and ribavirin therapy. The Swiss Hepatitis C Cohort Study Group. *Hepatology*. 2012 Apr;55(4):1038-47
81. Nicolosi Guidicelli S, Lopez-Guillermo A, Falcone U, Conconi A, Christinat A, Rodriguez-Abreu D, Grisanti S, Lobetti-Bodoni C, Piffaretti JC, Johnson PW, Mombelli G, Cerny A, Montserrat E, Cavalli F, Zucca E. Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group. *Hematol Oncol*. 2012 Sep;30(3):137-42.
82. Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B, Goossens N, Kuske L, Müllhaupt B, Gerlach T, Heim MH, Moradpour D, Cerny A, Malinverni R, Regenass S, Dollenmaier G, Hirsch H, Martinetti G, Gorgiewski M, Bourlière M, Poynard T, Theodorou I, Abel L, Pol S, Dufour JF, Negro F; on behalf of the Swiss Hepatitis C Cohort Study Group the ANRS HC EP 26 Genoscan Study Group. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. *Hepatology*. 2012 Feb;55(2):384-94

83. Wölk B, Trautwein C, Büchele B, Kersting N, Blum HE, Rammensee HG, Cerny A, Stevanovic S, Moradpour D, Brass V. Identification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands. *PLoS One*. 2012;7(1)
84. Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski JP, Tran A, Mathurin P, Thimme R, Arastéh K, Trautwein C, Cerny A, Dikopoulos N, Schuchmann M, Heim MH, Gerken G, Stern JO, Wu K, Abdallah N, Girlich B, Scherer J, Berger F, Marquis M, Kukolj G, Boecher W, Steffgen J Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. *J Hepatol*. 2012 Mar 10. [Epub ahead of print]
85. Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Müllhaupt B, Semela D, Dufour JF, Heim MH, Moradpour D, Cerny A, Malinverni R, Hirsch H, Martinetti G, Suppiah V, Stewart G, Booth DR, George J, Casanova JL, Bréchet C, Rice CM, Talal AH, Jacobson IM, Bourlière M, Theodorou I, Poynard T, Negro F, Pol S, Bochud PY, Abel L; Swiss Hepatitis C Cohort Study Group; International Hepatitis C Genetics Consortium; French ANRS HC EP 26 Genoscan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. *Gastroenterology*. 2012 Nov;143(5):1244-52
86. Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B, Frei P, Seifert B, Bischoff Ferrari HA, von Eckardstein A, Müllhaupt B, Geier A; Swiss Hepatitis C Cohort Study Group. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. *Antivir Ther*. 2012;17(3):541-7.
87. Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF, Geier A, Gerlach TJ, Heim MH, Malinverni R, Negro F, Regenass S, Badenhop K, Bojunga J, Sarrazin C, Zeuzem S, Müller T, Berg T, Bochud PY, Moradpour D, Swiss Hepatitis C Cohort Study Group. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. *PLoS One*. 2012;7(7)
88. Kuske L, Mensen A, Müllhaupt B, Negro F, Semela D, Moradpour D, Malé PJ, Heim MH, Malinverni R, Cerny A, Dufour JF; Swiss Hepatitis C Cohort Study. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. *Swiss Med Wkly*. 2012 Aug 6;142
89. Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF, Geier A, Gerlach TJ, Heim MH, Malinverni R, Negro F, Regenass S, Badenhop K, Bojunga J, Sarrazin C, Zeuzem S, Müller T, Berg T, Bochud PY, Moradpour D; Swiss Hepatitis C Cohort Study Group. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. *PLoS One*. 2012;7(7)
90. Girardin F, Daali Y, Gex-Fabry M, Rebsamen M, Roux-Lombard P, Cerny A, Bihl F, Binek J, Moradpour D, Negro F, Desmeules J; Swiss Hepatitis C Cohort Study Group. Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection. *J Viral Hepat*. 2012 Aug;19(8):568-73.
91. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA ; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. *N Engl J Med*. 2012 Apr 12;366(15):1404-13.
92. Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski JP, Tran A, Mathurin P, Thimme R, Arastéh K, Trautwein C, Cerny A, Dikopoulos N, Schuchmann M, Heim MH, Gerken G, Stern JO, Wu K, Abdallah N, Girlich B, Scherer J, Berger F, Marquis M,

Kukolj G, Böcher W, Steffgen J. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. *J Hepatol.* 57(1):39-46; 2012

93. Lange CM, Bibert S, Dufour JF, Cellerai C, Cerny A, Heim MH, Kaiser L, Malinverni R, Müllhaupt B, Negro F, Semela D, Moradpour D, Kutalik Z, Bochud PY; Swiss Hepatitis C Cohort Study Group. Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. *J Hepatol.* S0168-8278(13); 2013
94. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, Duong FH, Gerlach T, Malinverni R, Moradpour D, Negro F, Müllhaupt B, Bochud PY; Swiss Hepatitis C Cohort Study. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. *J Exp Med.* 3;210(6):1109-16; 2013
95. Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Müllhaupt B, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud PY; Hiroshima Liver Study Group; Swiss Hepatitis C Cohort Study Group. Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development. *PLoS One.* 29;8(5) 2013
96. Fretz R, Negro F, Bruggmann P, Lavanchy D, De Gottardi A, Pache I, Masserey Spicher V, Cerny A. Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection. *Swiss Med Wkly.* 17;143: 2013
97. Frei P, Leucht AK, Held U, Kofmehl R, Manser CN, Schmitt J, Mertens J, Rau M, Baur K, Gerlach T, Negro F, Heim M, Moradpour D, Cerny A, Dufour JF, Müllhaupt B, Geier A; on behalf of the Swiss Hepatitis C Cohort Study Group. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon alfa and ribavirin in chronic hepatitis C virus patients. *Liver Int.* 2013 Apr;34(4):551-7.
98. S, Marini G, Majno P, Mazzucchelli L, Spitale A. Survival of hepatocellular carcinoma patients is significantly improving: a population-based study from southern Switzerland. Bordoni A, Cerny A, Bihl F, Alerci M, Mazzola P, Peverelli. *Cancer Epidemiol.* 2014 Dec;38(6):679-85.
99. C. Rüeger S, Bochud PY, Dufour JF, Müllhaupt B, Semela D, Heim MH, Moradpour D, Cerny A, Malinverni R, Booth DR, Suppiah V, George J, Argiro L, Halfon P, Bourlière M, Talal AH, Jacobson IM, Patin E, Nalpas B, Poynard T, Pol S, Abel L, Kutalik Z, Negro F. Impact of common risk factors of fibrosis progression in chronic hepatitis *Gut.* 2014 Sep 11. pii: gutjnl-2014-306997.
100. Morard I, Clément S, Calmy A, Mangia A, Cerny A, De Gottardi A, Gorgievski M, Heim M, Malinverni R, Moradpour D, Müllhaupt B, Semela D, Pascarella S, Bochud PY, Negro F; Clinical significance of the CCR5 delta 32 allele in hepatitis C. Swiss Hepatitis C Cohort Study Group. *PLoS One.* 2014 Sep 5;9(9):e106424.

#### B) Reviews since 2008 (peer review)

23. Cerny A. Hepatitis C after simultaneous liver-kidney transplantation. *J Hepatol.* Nov;51(5):839-41, 2009
24. Schwendener RA, Ludewig B, Cerny A, Engler O: Liposome-based vaccines. *Methods Mol Biol* 605:163-75, 2010

25. [Management of the cirrhotic patient]. Pfefferle M, Bihl F, Terzioli B, Cerny A. *Ther Umsch.* 2011 Apr;68(4):207-11
26. Management of hepatitis C virus (HCV) infection in drug substitution programs. Witteck A, Schmid P, Hensel-Koch K, Thurnheer MC, Bruggmann P, Vernazza P; Swiss Hepatitis C and HIV Cohort Studies. *Swiss Med Wkly.* 2011 May 27;141
27. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. Swiss Association for the Study of the Liver. *Swiss Med Wkly.* 2012 Feb 24;142:w13516
28. [New aspects in sonography of the liver]. Hagara D, Schwarzenbach HR, Cerny A. *Praxis (Bern 1994).* 2012 Sep 5;101(18):1161-6